Telix Pharmaceuticals Acquires QSAM Biosciences

Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich

September 21, 2026

Pharmaceuticals

Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in contingent payments tied primarily to regulatory approvals and sales milestones for ITM-11. The deal combines Telix’s radiopharmaceutical development and commercial platform with ITM’s isotope manufacturing, distribution network, and therapeutic pipeline; it remains subject to shareholder and regulatory approvals.

Quanterix Completes Acquisition of Akoya Biosciences

July 8, 2025

Healthcare Services

Quanterix completed its previously announced acquisition of Akoya Biosciences under the amended merger agreement, issuing about 7.8 million shares and paying about $20 million in cash in the aggregate to Akoya holders. The companies positioned the deal as creating an integrated platform for measuring biomarkers across the blood and tissue continuum and expanding addressable markets.

Telix Pharmaceuticals to Acquire RLS (USA) to Expand North American Radiopharmacy Manufacturing and Distribution

September 22, 2024

Healthcare Services

Telix Pharmaceuticals Limited has agreed to acquire RLS (USA) Inc. from its parent company, RLS Group Ltd., to expand Telix’s North American radiopharmaceutical manufacturing and distribution platform. The deal leverages RLS’s 31 Joint Commission-accredited radiopharmacies to build a radiometal production and distribution network and improve capacity for PET, SPECT, and therapeutic isotopes.

Telix Pharmaceuticals Acquires ARTMS Inc.

March 5, 2024

Pharmaceuticals

Telix Pharmaceuticals Limited has completed the acquisition of ARTMS Inc., a Burnaby, British Columbia-based developer of cyclotron-based isotope production technology and the QUANTM Irradiation System (QIS). The deal strengthens Telix's vertical integration and supply-chain control for key diagnostic and therapeutic radioisotopes (including 89Zr, 68Ga, 99mTc and 64Cu) to support its commercial products and pipeline.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.

January 29, 2021

Biotechnology

Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.